- Home
- FAMI vs BBIO Comparison
FAMI vs BBIO Comparison
Compare FAMI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- BBIO
- Stock Information
- Founded
- FAMI 2015
- BBIO 2015
- Country
- FAMI China
- BBIO United States
- Employees
- FAMI N/A
- BBIO N/A
- Industry
- FAMI Packaged Foods
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- BBIO Health Care
- Exchange
- FAMI Nasdaq
- BBIO Nasdaq
- Market Cap
- FAMI 2.1M
- BBIO 6.7B
- IPO Year
- FAMI 2018
- BBIO 2019
- Fundamental
- Price
- FAMI $1.67
- BBIO $34.83
- Analyst Decision
- FAMI
- BBIO Strong Buy
- Analyst Count
- FAMI 0
- BBIO 12
- Target Price
- FAMI N/A
- BBIO $57.09
- AVG Volume (30 Days)
- FAMI 91.6K
- BBIO 3.2M
- Earning Date
- FAMI 05-20-2025
- BBIO 04-29-2025
- Dividend Yield
- FAMI N/A
- BBIO N/A
- EPS Growth
- FAMI N/A
- BBIO N/A
- EPS
- FAMI N/A
- BBIO N/A
- Revenue
- FAMI $64,131,332.00
- BBIO $127,415,000.00
- Revenue This Year
- FAMI N/A
- BBIO $13.67
- Revenue Next Year
- FAMI N/A
- BBIO $118.02
- P/E Ratio
- FAMI N/A
- BBIO N/A
- Revenue Growth
- FAMI N/A
- BBIO N/A
- 52 Week Low
- FAMI $1.43
- BBIO $21.62
- 52 Week High
- FAMI $11.28
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- FAMI 44.39
- BBIO 46.94
- Support Level
- FAMI $1.60
- BBIO $36.85
- Resistance Level
- FAMI $1.83
- BBIO $39.16
- Average True Range (ATR)
- FAMI 0.14
- BBIO 1.47
- MACD
- FAMI 0.02
- BBIO -0.07
- Stochastic Oscillator
- FAMI 27.91
- BBIO 25.61
About FAMI Farmmi Inc.
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.